Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy

Dendritic cells (DCs) have the potential to elicit long-lasting anti-tumour immune responses. Most of the clinical trials of anti-cancer DC vaccines are based on monocyte-derived DCs (Mo-DCs). However, their outcomes have shown limited promise especially in multiple myeloma (MM) patients. Here, we i...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinde, Prajakta, Fernandes, Sophia, Melinkeri, Sameer, Kale, Vaijayanti, Limaye, Lalita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890285/
https://www.ncbi.nlm.nih.gov/pubmed/29632307
http://dx.doi.org/10.1038/s41598-018-23943-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890285/
https://www.ncbi.nlm.nih.gov/pubmed/29632307
http://dx.doi.org/10.1038/s41598-018-23943-w

Ejemplares similares